Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148142 | 1.00 | RORC (0.49) | RORCKDM1AKDM1BNAMPTDPP4 | |
| SCHEMBL148143 | 1.00 | RORC (0.49) | RORCKDM1AKDM1BNAMPTDPP4 | |
| SCHEMBL1725669 | 1.00 | RORC (0.49) | RORCKDM1AKDM1BNAMPTDPP4 | |
| SCHEMBL528557 | 0.90 | RORC (0.45) | RORCNAMPTDPP4USP30GPR119 | |
| SCHEMBL527742 | 0.89 | DPP4 (0.45) | RORCNAMPTDPP4USP30TACR1 | |
| SCHEMBL529014 | 0.89 | GPR119 (0.49) | DPP4USP30TACR1GPR119MEN1 | |
| SCHEMBL1968429 | 0.85 | DPP4 (0.46) | RORCDPP4USP30PDE4B | |
| SCHEMBL527646 | 0.85 | DPP4 (0.53) | RORCNAMPTDPP4USP30GPR119 | |
| SCHEMBL16780215 | 0.84 | RORC (0.51) | RORCNAMPTUSP30TACR1GPR119 | |
| SCHEMBL13858400 | 0.84 | RORC (0.51) | RORCNAMPTUSP30TACR1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | RORC 631/4885KDM1A 4195/4885KDM1B 2993/4885 |
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | RORC 841/4885KDM1A 4417/4885KDM1B 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.